Drug Resistance Updates

Papers
(The TQCC of Drug Resistance Updates is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Editorial Board436
Editorial Board278
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor219
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma205
Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea181
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer167
Modulating undruggable targets to overcome cancer therapy resistance159
Novel nanomedicines to overcome cancer multidrug resistance145
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor144
Profiling the landscape of carbapenem resistance and hypervirulence in Klebsiella pneumoniae: A global epidemiological analysis of the plasmidome139
Unraveling the secrets: Evolution of resistance mediated by membrane proteins130
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance128
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects110
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma107
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer107
Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies106
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China105
Evolution of RND efflux pumps in the development of a successful pathogen105
Editorial Board105
A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis104
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae101
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance101
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer87
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine83
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges80
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma79
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs75
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond73
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation72
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer72
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC71
Targeting anoikis resistance as a strategy for cancer therapy69
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs66
Editorial Board61
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer61
Novel mobile colistin resistance gene mcr-4.9 in Vibrio cholerae from migratory birds58
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress57
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica55
Research progress on gene mutations and drug resistance in leukemia55
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers55
Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights53
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma51
Current therapy and drug resistance in metastatic castration-resistant prostate cancer50
Overcoming cancer chemotherapy resistance by the induction of ferroptosis49
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity48
Editorial Board48
Emergence of novel Klebsiella pneumoniae ST types with multidrug resistance in clinic46
Editorial Board46
ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C46
Global, regional, and national disease burden of multidrug-resistant tuberculosis without extensive drug resistance, 1990–2021: Findings from the Global Burden of Disease Study 202145
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy44
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment41
Autophagy in cancer development, immune evasion, and drug resistance41
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade41
Organoid models of drug resistant gastric adenosquamous carcinoma: Recapitulating tumor features and refining precision treatment41
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance41
Global distribution and genomic characteristics of carbapenemase-producing Escherichia coli among humans, 2005–202341
MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma40
Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma39
Hypoxia as a driver of resistance to immunotherapy38
CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer38
Targeting SLC7A11 with sorafenib sensitizes stereotactic body radiotherapy in colorectal cancer liver metastasis38
CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance37
Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer36
Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins35
LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein35
Acetate utilization promotes hormone therapy resistance in prostate cancer through neuroendocrine differentiation34
Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer34
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer34
Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae33
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer33
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerability32
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance32
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance32
Characterization of NMCR-3, NMCR-4 and NMCR-5, three novel non-mobile colistin resistance determinants: Implications for MCR-3, MCR-7, and MCR-5 progenitors, respectively31
Breaking the barrier: Epigenetic strategies to combat platinum resistance in colorectal cancer31
NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-131
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA31
Editorial Board30
Editorial Board30
Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP30
0.082751035690308